Solid phase binding assay - Clusterin binding to Very Low-Density Lipoprotein Receptor (VLDLR)

Research Community
Research Community

ASAP supports three programs and serves as a member of multiple consortia to advance research for the benefit of the global Parkinson’s disease community.
Explore
Highlights
Highlights

ASAP shares the impact that our initiative, network, and supported programs have had on providing new insights into Parkinson’s disease. Discover news, interviews, awards, and annual impact.
Explore
Open Science
Open Science

ASAP is dedicated to facilitating a research environment where meaningful collaboration, research-enabling resources, and data sharing provides the answers we need to understand, diagnose, and treat Parkinson’s disease. Discover our open science philosophy.
Explore
Tools & Resources
Tools & Resources

ASAP is committed to developing and openly sharing research outputs, including data, code, protocols, and key lab materials, to help the scientific community build upon existing work.
Explore

Description

This protocol details how to monitor Clusterin binding to the Very Low-Density Lipoprotein Receptor (VLDLR) by Enzyme-linked immunosorbent assays (ELISA) adapted from Leeb et al. (2014).

Identifier (DOI)

10.17504/protocols.io.yxmvm36kol3p/v1

Tags

CLU (Clusterin)
ELISA
Protein aggregates

Discovery Team

Team Harper

Program

Collaborative Research Network

Theme

PD Functional Genomics

Meet the Authors

Patricia Yuste Checa

External Collaborator
Andreas Bracher

External Collaborator
Franz-Ulrich Hartl, MD

Co-PI (Core Leadership): Team Harper,

Max Planck Institute of Biochemistry

Solid phase binding assay – Clusterin binding to Very Low-Density Lipoprotein Receptor (VLDLR)

Output Details

Meet the Authors

Patricia Yuste Checa

Andreas Bracher

Franz-Ulrich Hartl, MD

Related Research

Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases

The chaperone Clusterin in neurodegeneration−friend or foe?

HEK293E_Clu TL1